Ajovy Injection
Product Images NDC 51759-202

Product Visual Gallery

This gallery contains 32 technical images submitted to the FDA as part of the official labeling for Ajovy (NDC 51759-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 1)

A line graph depicting change from baseline in monthly migraine days over three months. It compares three groups: Placebo, AJOVY 675 mg quarterly, and AJOVY 225 mg monthly. The x-axis represents time in months (Baseline, Month 1, Month 2, Month 3), and the y-axis shows change in monthly migraine days. Both AJOVY groups show a greater reduction in migraine days compared to placebo, with least-square means and standard error indicated.*

FDA Label Image

Clock Image (Image 10)

An illustration of a round stopwatch or timer displaying "30 minutes" in black text centered on a white background. The stopwatch has three small knobs on the top and sides.*

FDA Label Image

Figure E (Image 11)

An instructional illustration showing a close-up view of an AJOVY 225 mg/1.5 mL subcutaneous injection pen. The image highlights a viewing window on the pen for monitoring the medication inside during use. The pen is white with a dark gray cap and includes the AJOVY brand name and fremanezumab-vfrm labeling.*

FDA Label Image

Figure F (Image 12)

An instructional illustration showing three recommended subcutaneous injection sites for AJOVY (fremanezumab-vfrm) injection. The sites highlighted include the abdomen below the waistline, the front of the thighs, and the back of the upper arm near the shoulder.*

FDA Label Image

Figure G (Image 13)

An instructional illustration showing two hands demonstrating the removal of a cap from a syringe. The right hand holds the syringe body, while the left hand pulls the cap straight off, indicated by a blue arrow pointing to the right.*

FDA Label Image

Step 9 Image (Image 14)

An instructional illustration showing a hand holding an AJOVY (fremanezumab-vfrm) subcutaneous injection device at a 90-degree angle to the skin. This image demonstrates the proper angle for administering the 225 mg/1.5 mL dosage injection.*

FDA Label Image

Figure H (Image 15)

An instructional diagram showing the step-by-step use of an AJOVY (fremanezumab-vfrm) 225 mg/1.5 mL subcutaneous injection pen. The sequence depicts pressing the injector down to hear a first click, continuing to hold down until a second click, then keeping the injector pressed for 10 seconds to complete the injection.*

FDA Label Image

Step 12 Image (Image 16)

An instructional illustration showing how to hold the AJOVY injection pen at a 90-degree angle for a subcutaneous injection. The image highlights the gray stopper on the pen and depicts the direction to pull or push the injection device during use.*

FDA Label Image

Carton Part 1 (Image 17)

An instructional illustration showing a hand disposing of a used injection device into a red sharps container, demonstrating proper disposal of a subcutaneous injection pen or syringe.*

FDA Label Image

Carton Part 2 (Image 18)

An instructional diagram labeling parts of a syringe used for subcutaneous injection. It identifies the needle cap, needle, syringe body, expiration date (EXP), finger flange, plunger, and thumb pad. The syringe is likely associated with AJOVY (fremanezumab-vfrm) injection, 225 mg/1.5 mL by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image 19

Illustration of a prefilled syringe labeled Ajovy (fremanezumab-vfrm) for subcutaneous injection, showing details including the syringe barrel, plunger, needle, and an expiration date area. The syringe is designed for delivering a 225 mg/1.5 mL dose.*

FDA Label Image

Figure 2 (Image 2)

A bar chart comparing the percentage of patients experiencing varying reductions in monthly migraine days. The chart shows data for Placebo (N=290), AJOVY 675 mg Quarterly (N=288), and AJOVY 225 mg Monthly (N=287) groups, with the x-axis representing ranges of fewer migraine days per month and the y-axis showing the percentage of patients. The chart includes categories from more than 12 to 14 fewer days to no change or more migraine days.*

FDA Label Image

Image 20

FDA Label Image

Image 21

An instructional illustration showing a hand holding an AJOVY (fremanezumab-vfrm) prefilled syringe for subcutaneous injection. The syringe is labeled with the product name and strength of 225 mg/1.5 mL.*

FDA Label Image

Image 22

An instructional illustration showing items related to administering AJOVY injection. It includes a gauze pad or cotton ball, an alcohol swab, a red sharps container, and a prefilled syringe labeled AJOVY. The diagram visually depicts the materials used in the subcutaneous injection process for AJOVY.*

FDA Label Image

Image 23

Illustration of a stopwatch showing 30 minutes, likely indicating a timing instruction or interval.*

FDA Label Image

Image 24

An illustration showing an AJOVY (fremanezumab-vfrm) 225 mg/1.5 mL subcutaneous injection syringe with a focused view of the label area on the syringe. The image highlights the importance of checking the label before use, indicated visually by an eye symbol.*

FDA Label Image

Image 25

Illustration showing injection sites for AJOVY (fremanezumab-vfrm) subcutaneous injection. It depicts three areas on the human body recommended for injection: the abdomen (excluding the navel area), the upper outer thighs, and the back of the upper arms.*

FDA Label Image

Image 26

An instructional illustration showing a prefilled syringe and its needle cap with an arrow indicating that the needle cap should not be put back on the syringe. A warning note states, "Do not put the needle cap back on the prefilled syringe." This visual cautions against recapping the needle after use.*

FDA Label Image

Image 27

Instructional illustration showing the technique for subcutaneous injection. The series depicts pinching the skin, inserting the needle at a 45 to 90-degree angle, followed by depressing the plunger to administer the injection, and finally removing the syringe from the skin.*

FDA Label Image

Image 28

An instructional illustration showing a hand holding a syringe with the needle pointed downward, positioned above the skin. An arrow points upward from the syringe, indicating the motion direction for the injection or needle removal. This diagram is related to subcutaneous injection technique.*

FDA Label Image

Image 29

An instructional illustration showing a hand disposing of a syringe into a red sharps container, indicating proper disposal of injection needles following subcutaneous administration.*

FDA Label Image

Figure 3 (Image 3)

A line graph comparing change from baseline in monthly headache days of at least moderate severity over three months among three groups: placebo, AJOVY 675 mg quarterly, and AJOVY 225 mg monthly dosing. The y-axis shows change from baseline in days, and the x-axis shows time points at baseline, month 1, month 2, and month 3, with data points and error bars for each group.*

FDA Label Image

Image 30

The folding carton label for AJOVY (fremanezumab-vfrm) injection, 225 mg/1.5 mL, by Teva Pharmaceuticals USA, Inc. The label includes dosing information indicating subcutaneous injection using a single-dose prefilled syringe. The front panel features the AJOVY brand name prominently, along with the dosage strength and product designation. The label references the website www.AJOVY.com for tips, resources, and instructional videos on usage. There are areas marked for opening instructions and a barcode is also visible.*

FDA Label Image

Image 31

AJOVY (fremanezumab-vfrm) injection 225 mg/1.5 mL subcutaneous injection packaging label. The label shows the Teva Pharmaceuticals USA, Inc. branding and includes website information for usage instructions. It features the product name, strength, dosage form, and the NDC numbers. The packaging design uses a white background with blue, green, and purple accents.*

FDA Label Image

Image 32

Packaging label for AJOVY (fremanezumab-vfrm) injection, 225 mg/1.5 mL strength, a subcutaneous injection. The label displays the product name, dosage form, strength, and route. It is labeled by Teva Pharmaceuticals USA, Inc. The design includes instructions to visit www.AJOVY.com for usage resources. The label features a white background with green and pink accents.*

FDA Label Image

Figure 4 (Image 4)

A bar chart comparing the percentage of patients achieving various reductions in headache days of at least moderate severity per month. The chart shows data for three groups: placebo, AJOVY 675 mg quarterly, and AJOVY 225 mg monthly. The horizontal axis displays ranges of headache day reductions, and the vertical axis indicates the percentage of patients. A separate category shows patients with no change or more headache days per month.*

FDA Label Image

Figure A (Image 5)

An illustration of the AJOVY (fremanezumab-vfrm) subcutaneous injection pen showing labeled parts including the protective cap, needle shield, expiration date (EXP), and viewing window. The pen is cylindrical with a label displaying the product name and generic name.*

FDA Label Image

Figure B (Image 6)

An instructional diagram of an AJOVY (fremanezumab-vfrm) 225 mg/1.5 mL subcutaneous injection pen by Teva Pharmaceuticals USA, Inc. The illustration highlights the blue plunger and gray stopper components of the injection device.*

FDA Label Image

Stop Image (Image 7)

FDA Label Image

Figure C (Image 8)

An instructional illustration showing a hand lifting or pulling an Ajovy injection device (225 mg/1.5 mL) out of its tray or packaging, with an upward arrow indicating the direction to remove the device. The device is rectangular with visible blue and pink label elements.*

FDA Label Image

Figure D (Image 9)

Illustration showing components for administering AJOVY subcutaneous injection, including a gauze pad or cotton ball, an alcohol swab, a sharps container, and the AJOVY prefilled autoinjector device labeled with the product name.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.